Genmab A/S ADR (GMAB)

$33.56 +1.44 (4.48%)
Market Cap 21.53B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 18.78
Forward PE 18.51
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 4,157,700
Avg Vol 1,602,716
Day's Range N/A - N/A
Shares Out 641.59M
Stochastic %K 99%
Beta 0.98
Analysts Strong Sell
Price Target $34.54

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
CDMO
CDMO Oct. 3 at 3:04 PM
$GMAB it did nothing for months and now its up up up up. Maybe merus acquisition is liked by people. I think it is a too big for them and i am skeptical tbh. Brings a lot of cash burn
1 · Reply
stockpicker63
stockpicker63 Oct. 3 at 2:25 PM
$GMAB Free tip nice profit above +8%
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
HC Wainwright & Co. has updated their rating for Genmab ( $GMAB ) to Buy with a price target of 40.
0 · Reply
smartkarma
smartkarma Oct. 1 at 10:57 PM
$GMAB | GMAB's $5B Power Play: Is Merus The Missing Piece In Its Cancer War Chest? "With Merus’s market capitalization surging over 60% YTD to $5.2 billion, Genmab appears to be positioning itself for a strategic leap in the immuno-oncology arena." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/gmab-s-5b-power-play-is-merus-the-missing-piece-in-its-cancer-war-chest
0 · Reply
stockpicker63
stockpicker63 Sep. 30 at 2:23 PM
$GMAB "Technical breakout! 🚀 $GMAB just pushed above $30.46 resistance with strong momentum. Chart shows plenty of upside room — potential +10% move in sight if volume holds. 📈 #Stocks #Breakout"
0 · Reply
stockpicker63
stockpicker63 Sep. 30 at 2:17 PM
Look at $GMAB for a break-out above $30.45
0 · Reply
Pika_Capital
Pika_Capital Sep. 30 at 1:47 PM
$GMAB train is gone. Welcome 30s
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:23 AM
$MRAL Graniteshares 2X Long $MARA ETF: 62 trades, $95K vs $36K avg (2.65x !!). $75K calls / $20K puts. $YMM Full Truck Alliance: 60 trades, $81K vs $72K avg (1.13x). $75K calls / $7K puts. $SDGR Schrodinger: 135 trades, $75K vs $99K avg (0.76x). $75K calls / $333 puts. $GMAB Genmab A/S: 19 trades, $74K vs $13K avg (5.66x !!). $74K calls / $30 puts.
0 · Reply
BigManThings12
BigManThings12 Sep. 30 at 6:37 AM
$GMAB what do we think of the acquisition of $MRUS ???
0 · Reply
Pika_Capital
Pika_Capital Sep. 29 at 2:23 PM
$GMAB quite a buy here $MRUS Long gmab since cash flow will keep coming regardless
0 · Reply
Latest News on GMAB
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Sep 30, 2025, 9:59 PM EDT - 4 days ago

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

MRUS

Genmab A/S (GMAB) M&A Call Transcript

Sep 29, 2025, 5:47 PM EDT - 5 days ago

Genmab A/S (GMAB) M&A Call Transcript

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Sep 29, 2025, 10:15 AM EDT - 5 days ago

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

MRUS

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Sep 29, 2025, 7:36 AM EDT - 5 days ago

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

MRUS

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Sep 29, 2025, 3:23 AM EDT - 6 days ago

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

MRUS

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 6 days ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

MRUS

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 29, 2025, 1:14 AM EDT - 6 days ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

MRUS

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Sep 25, 2025, 7:14 PM EDT - 9 days ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 25, 2025, 3:17 AM EDT - 10 days ago

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Major Shareholder Announcement

Sep 23, 2025, 9:18 AM EDT - 11 days ago

Major Shareholder Announcement

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Sep 14, 2025, 8:31 AM EDT - 20 days ago

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Sep 12, 2025, 1:58 PM EDT - 22 days ago

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Genmab: A Matter Of Time

Sep 12, 2025, 6:15 AM EDT - 22 days ago

Genmab: A Matter Of Time

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:41 PM EDT - 25 days ago

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Sep 9, 2025, 2:57 PM EDT - 25 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Sep 9, 2025, 2:54 PM EDT - 25 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

10 stocks to consider if you want alternatives to the expensive S&P 500

Sep 9, 2025, 2:39 PM EDT - 25 days ago

10 stocks to consider if you want alternatives to the expensive S&P 500

SPY AEG EFA NGG

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sep 3, 2025, 8:30 AM EDT - 4 weeks ago

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 26, 2025, 9:31 AM EDT - 5 weeks ago

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Aug 26, 2025, 8:00 AM EDT - 5 weeks ago

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Aug 8, 2025, 1:23 PM EDT - 2 months ago

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

ABBV

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:18 PM EDT - 2 months ago

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Genmab Announces Financial Results for the First Half of 2025

Aug 7, 2025, 11:08 AM EDT - 2 months ago

Genmab Announces Financial Results for the First Half of 2025

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Aug 7, 2025, 10:31 AM EDT - 2 months ago

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 2 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 2 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Jul 16, 2025, 6:29 AM EDT - 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Genmab Announces Changes to its Executive Committee

Jul 1, 2025, 8:00 AM EDT - 3 months ago

Genmab Announces Changes to its Executive Committee

Completion of Share Buy-back Program

Jun 30, 2025, 9:30 AM EDT - 3 months ago

Completion of Share Buy-back Program

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Jun 23, 2025, 9:18 AM EDT - 3 months ago

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Transactions in Connection with Share Buy-back Program

Jun 23, 2025, 8:19 AM EDT - 3 months ago

Transactions in Connection with Share Buy-back Program

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Jun 15, 2025, 5:00 AM EDT - 3 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Jun 2, 2025, 2:30 PM EDT - 4 months ago

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

May 27, 2025, 9:55 AM EDT - 4 months ago

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:05 PM EDT - 4 months ago

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

May 21, 2025, 10:02 AM EDT - 4 months ago

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology

May 19, 2025, 7:03 AM EDT - 4 months ago

Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 10:15 AM EDT - 5 months ago

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025, 11:01 AM EDT - 5 months ago

Genmab Announces Financial Results for the First Quarter of 2024

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 1, 2025, 8:24 PM EDT - 5 months ago

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15, 2025, 7:36 AM EDT - 6 months ago

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Apr 15, 2025, 6:22 AM EDT - 6 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab A/S Share Capital Reduction

Apr 10, 2025, 12:20 PM EDT - 6 months ago

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Apr 7, 2025, 7:43 AM EDT - 6 months ago

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Apr 1, 2025, 3:53 PM EDT - 6 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Mar 31, 2025, 11:20 AM EDT - 6 months ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

Mar 31, 2025, 8:18 AM EDT - 6 months ago

Transactions in connection with share buy-back program

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Mar 27, 2025, 2:27 PM EDT - 6 months ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Mar 27, 2025, 8:00 AM EDT - 6 months ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Mar 25, 2025, 5:28 PM EDT - 6 months ago

Genmab Announces Initiation of Share Buy-Back Program

CDMO
CDMO Oct. 3 at 3:04 PM
$GMAB it did nothing for months and now its up up up up. Maybe merus acquisition is liked by people. I think it is a too big for them and i am skeptical tbh. Brings a lot of cash burn
1 · Reply
stockpicker63
stockpicker63 Oct. 3 at 2:25 PM
$GMAB Free tip nice profit above +8%
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
HC Wainwright & Co. has updated their rating for Genmab ( $GMAB ) to Buy with a price target of 40.
0 · Reply
smartkarma
smartkarma Oct. 1 at 10:57 PM
$GMAB | GMAB's $5B Power Play: Is Merus The Missing Piece In Its Cancer War Chest? "With Merus’s market capitalization surging over 60% YTD to $5.2 billion, Genmab appears to be positioning itself for a strategic leap in the immuno-oncology arena." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/gmab-s-5b-power-play-is-merus-the-missing-piece-in-its-cancer-war-chest
0 · Reply
stockpicker63
stockpicker63 Sep. 30 at 2:23 PM
$GMAB "Technical breakout! 🚀 $GMAB just pushed above $30.46 resistance with strong momentum. Chart shows plenty of upside room — potential +10% move in sight if volume holds. 📈 #Stocks #Breakout"
0 · Reply
stockpicker63
stockpicker63 Sep. 30 at 2:17 PM
Look at $GMAB for a break-out above $30.45
0 · Reply
Pika_Capital
Pika_Capital Sep. 30 at 1:47 PM
$GMAB train is gone. Welcome 30s
0 · Reply
highnihilism
highnihilism Sep. 30 at 9:23 AM
$MRAL Graniteshares 2X Long $MARA ETF: 62 trades, $95K vs $36K avg (2.65x !!). $75K calls / $20K puts. $YMM Full Truck Alliance: 60 trades, $81K vs $72K avg (1.13x). $75K calls / $7K puts. $SDGR Schrodinger: 135 trades, $75K vs $99K avg (0.76x). $75K calls / $333 puts. $GMAB Genmab A/S: 19 trades, $74K vs $13K avg (5.66x !!). $74K calls / $30 puts.
0 · Reply
BigManThings12
BigManThings12 Sep. 30 at 6:37 AM
$GMAB what do we think of the acquisition of $MRUS ???
0 · Reply
Pika_Capital
Pika_Capital Sep. 29 at 2:23 PM
$GMAB quite a buy here $MRUS Long gmab since cash flow will keep coming regardless
0 · Reply
EarlyBirdEmail
EarlyBirdEmail Sep. 29 at 10:45 AM
$OXY $SOL.X $GMAB $MRUS Investors in Occidental Petroleum who are familiar with the energy giant’s debt woes may need to prepare for another divestment. https://www.earlybird.email/p/occidental-explores-oxychem-sale
0 · Reply
DonCorleone77
DonCorleone77 Sep. 29 at 10:25 AM
$MRUS $GMAB Genmab acquires Merus for $97 per share in cash or $8B
0 · Reply
notreload_ai
notreload_ai Sep. 29 at 10:21 AM
$GMAB is buying $MRUS for $8 billion ($97/share) to secure a late-stage, breakthrough drug called petosemtamab which treats head and neck cancer. This deal speeds up Genmab's shift into a global biotech leader. https://notreload.xyz/genmab-merus-petosemtamab-8b-acquisition/
0 · Reply
SenefAS
SenefAS Sep. 29 at 9:15 AM
Monday buyout $GMAB GENMAB TO ACQUIRE $MRUS MERUS FOR $97 PER SHARE IN AN ALL-CASH TRANSACTION VALUED AT $8 BILLION #biotech $XBI $IBB
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 6:59 AM
$GMAB Excellent article that nails exactly where GMAB stands right now. So if you want to update your GMAB knowledge or get acquainted with GMAB, this is a must read. https://beyondspx.com/quote/GMAB/analysis/genmab-s-ascent-proprietary-antibodies-powering-a-new-era-of-oncology-leadership-nasdaq-gmab
0 · Reply
Broview
Broview Sep. 25 at 7:27 AM
$GMAB why no chart?
1 · Reply
CDMO
CDMO Sep. 24 at 9:44 PM
$GMAB finally green here
0 · Reply
Pika_Capital
Pika_Capital Sep. 24 at 3:23 PM
$GMAB almost 30. At $20 this was such a no brainer buy
0 · Reply
Biotekman
Biotekman Sep. 19 at 3:31 PM
$CRMD Is now my 2nd largest position (just behind $GMAB)
0 · Reply
gimoozaabi
gimoozaabi Sep. 17 at 1:59 AM
$XERS came across this I may be tripping here, but I don’t recall seeing $GMAB in any prior Xeris news
1 · Reply
PetrCZE
PetrCZE Sep. 11 at 11:57 AM
$GMAB What a ride last month!
0 · Reply
Pika_Capital
Pika_Capital Sep. 3 at 4:29 PM
$GMAB most likely you wont see $20 again here. Those bargain prices are gone but everything under $30 is a buy imo if you are patient to hold for few years.
2 · Reply